FindTrial
Sign In

To Determine the Role of Beta Blocker in Splenic Stiffness in Patients with Liver Cirrhosis

Effect of Beta Blocker Therapy on Splenic Stiffness in Patients with Cirrhosis of Liver Having High Risk Esophageal Varices

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/05/042718
Enrollment
100
Registered
2022-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age of 18 and more than 18, irrespective of the gender Patients with chronic liver disease with high risk esophageal varices

Exclusion criteria

Exclusion criteria: Patient are already on beta blocker Extrahepatic portal vein obstruction Hepatocellular carcinoma Patients diagnosed with organ failure Pregnancy

Design outcomes

Primary

MeasureTime frame
To look for change in splenic stiffness after 2 months of beta blocker therapyTimepoint: 2 months—

Secondary

MeasureTime frame
To look for change in liver stiffness after 2 months To look for change in CTP and MELD score after 2 months Timepoint: 2 months—

Countries

India

Contacts

Public ContactDr Raya Venkateswara Reddy

Manipal Academy of Higher Education

venky.medical99@gmail.com9502417051

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026